A combined inhibition therapy of Shh pathway and MEK or AKT, has been shown to produce synergistic effects in reducing melanoma and cholangiocarcinoma cell proliferation in vitro [31]. The gene discussed is AKT1; the disease is cholangiocarcinoma.